Irene Dalai

TL;DR: In this paper, the authors performed whole-genome sequencing of 102 primary pancreatic neuroendocrine tumours and defined the genomic events that characterize their pathogenesis, including a deficiency in G:C,>T:A base excision repair due to inactivation of MUTYH, which encodes a DNA glycosylase.

TL;DR: The results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors and raises the potential for SSTR expression to be evaluated as a marker of response to somatostatin analogs.

TL;DR: The vast majority of PETs showed qualitative and/or quantitative alterations in menin localization, and in 30% of cases, this was associated with MEN1 mutations affecting sequences involved in nuclear localization or protein-protein interaction.

TL;DR: The data support a pro-survival role of BCR signaling in MCL and suggest that this pathway might be a candidate for therapy and also suggest that Syk activation patterns might be different in M CL compared to other lymphoma subtypes.

TL;DR: Treatment with long-acting release octreotide was associated with stabilization of disease and a good quality of life in 38% of patients and a Ki-67 index>or=5% and/or the presence of weight loss may justify more aggressive therapy without waiting for radiologically proven progression of disease.